Chemotherapy-induced anemia: the story of darbepoetin alfa

References

• Curt GA. Impact of fatigue on quality of life in oncology patients. Semin Hematol 2000;37(Suppl 6):14-17
   PubMed Web of Science ®Google Scholar
• Kleinman L, Benjamin K, Viswanathan H, et al. The anemia impact measure (AIM): development and content validation of a patient-reported outcome measure of anemia symptoms and symptom impacts in cancer patients receiving chemotherapy. Qual Life Res 2012;21:1255-66
   PubMed Web of Science ®Google Scholar
• Ludwig H, Van Belle S, Barrett-Lee P, et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004;40:2293-306
   PubMed Web of Science ®Google Scholar
• Knight K, Wade S, Balducci L. Prevalence and outcomes of anemia in cancer: a systematic review of the literature. Am J Med 2004;116(Suppl 7A):11-26S
   PubMed Web of Science ®Google Scholar
• Cella D, Kallich J, McDermott A, et al. The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: results from five randomized clinical trials. Ann Oncol 2004;15:979-86
   PubMed Web of Science ®Google Scholar
• Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999;91:1616-34
   PubMed Web of Science ®Google Scholar
• Alter HJ, Klein HG. The hazards of blood transfusion in historical perspective. Blood 2008;112:2617-26
   PubMed Web of Science ®Google Scholar
• Cunningham RS. Anemia in the oncology patient: cognitive function and cancer. Cancer Nurs 2003;26(Suppl):38-42S
   PubMed Web of Science ®Google Scholar
• Ludwig H, Fritz E. Anemia in cancer patients. Semin Oncol 1998;25(Suppl 7):2-6
   PubMedGoogle Scholar
• Marik PE, Corwin HL. Efficacy of red blood cell transfusion in the critically ill: a systematic review of the literature. Crit Care Med 2008;36:2667-74
   PubMed Web of Science ®Google Scholar
• Popovsky MA. Transfusion and lung injury. Transfus Clin Biol 2001;8:272-77
   PubMed Web of Science ®Google Scholar
• Obouzar N, Levache CB, Desrosiers M-P, et al. Patient time burden associated with red blood cell transfusions in cancer patients receiving chemotherapy in outpatient centers in France. 17th Congress of the European Hematology Association, 2012
   Google Scholar
• Lin FK, Suggs S, Lin CH, et al. Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci USA 1985;82:7580-4
   PubMed Web of Science ®Google Scholar
• Cascinu S, Fedeli A, Del FE, et al. Recombinant human erythropoietin treatment in cisplatin-associated anemia: a randomized, double-blind trial with placebo. J Clin Oncol 1994;12:1058-62
   PubMed Web of Science ®Google Scholar
• Wauters I, Vansteenkiste J. Erythropoiesis-stimulating agents in cancer patients: reflections on safety. Expert Rev Clin Pharmacol 2011;4:467-76
   PubMedGoogle Scholar
• Gregory SA. Efficacy of darbepoetin alfa in the treatment of chemotherapy-induced anemia in non-Hodgkin's lymphoma. Support Cancer Ther 2006;3:232-39
   PubMedGoogle Scholar
• Hedenus M, Adriansson M, San MJ, et al. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br J Haematol 2003;122:394-403
   PubMed Web of Science ®Google Scholar
• Littlewood TJ, Bajetta E, Nortier JW, et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001;19:2865-74
   PubMed Web of Science ®Google Scholar
• Vansteenkiste J, Pirker R, Massuti B, et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002;94:1211-20
   PubMed Web of Science ®Google Scholar
• Egrie JC, Dwyer E, Browne JK, et al. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol 2003;31:290-9
   PubMed Web of Science ®Google Scholar
• Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer 2001;84(Suppl 1):3-10
   PubMed Web of Science ®Google Scholar
• Glaspy J, Jadeja JS, Justice G, et al. A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy. Br J Cancer 2001;84(Suppl 1):17-23
   PubMed Web of Science ®Google Scholar
• Heatherington AC, Schuller J, Mercer AJ. Pharmacokinetics of novel erythropoiesis stimulating protein (NESP) in cancer patients: preliminary report. Br J Cancer 2001;84(Suppl 1):11-16
   PubMed Web of Science ®Google Scholar
• Elliott S, Egrie J, Browne J, et al. Control of rHuEPO biological activity: the role of carbohydrate. Exp Hematol 2004;32:1146-55
   PubMed Web of Science ®Google Scholar
• Elliott S, Lorenzini T, Asher S, et al. Enhancement of therapeutic protein in vivo activities through glycoengineering. Nat Biotechnol 2003;21:414-21
   PubMed Web of Science ®Google Scholar
• Heatherington AC, Dittrich C, Sullivan JT, et al. Pharmacokinetics of darbepoetin alfa after intravenous or subcutaneous administration in patients with non-myeloid malignancies undergoing chemotherapy. Clin Pharmacokinet 2006;45:199-211
   PubMed Web of Science ®Google Scholar
• Heatherington AC, Rovetti R, Kotasek D, et al. Predictability of pharmacokinetic properties of NESP administered once every 3 weeks in patients with non-myeloid malignancies receiving cyclic chemotherapy. Proc Am Soc Clin Oncol 2001;20: abstr 471
   Google Scholar
• Wauters I, Pat K, Vansteenkiste J. Flexible dosing with darbepoetin alfa for the treatment of chemotherapy-induced anemia. Ther Clin Risk Manag 2006;2:175-86
   PubMedGoogle Scholar
• Hedenus M, Hansen S, Taylor K, et al. Randomized, dose-finding study of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies. Br J Haematol 2002;119:79-86
   PubMed Web of Science ®Google Scholar
• Vansteenkiste J, Tomita D, Rossi G, Pirker R. Darbepoetin alfa in lung cancer patients on chemotherapy: a retrospective comparison of outcomes in patients with mild versus moderate-to-severe anaemia at baseline. Support Care Cancer 2004;12:253-62
   PubMed Web of Science ®Google Scholar
• Kotasek D, Steger G, Faught W, et al. Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study. Eur J Cancer 2003;39:2026-34
   PubMed Web of Science ®Google Scholar
• Canon JL, Vansteenkiste J, Bodoky G, et al. Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia. J Natl Cancer Inst 2006;98:273-84
   PubMed Web of Science ®Google Scholar
• Glaspy J, Vadhan-Raj S, Patel R, et al. Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial. J Clin Oncol 2006;24:2290-7
   PubMed Web of Science ®Google Scholar
• Glaspy JA, Jadeja JS, Justice G, et al. Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. Br J Cancer 2002;87:268-76
   PubMed Web of Science ®Google Scholar
• Glaspy JA, Tchekmedyian NS. Darbepoetin alfa administered every 2 weeks alleviates anemia in cancer patients receiving chemotherapy. Oncology (Williston Park) 2002;16(Suppl 11):23-9
   PubMedGoogle Scholar
• Schwartzberg LS, Yee LK, Senecal FM, et al. A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer. Oncologist 2004;9:696-707
   PubMed Web of Science ®Google Scholar
• Schwartzberg L, Burkes R, Mirtsching B, et al. Comparison of darbepoetin alfa dosed weekly (QW) vs. extended dosing schedule (EDS) in the treatment of anemia in patients receiving multicycle chemotherapy in a randomized, phase 2, open-label trial. BMC Cancer 2010;10:581
   PubMed Web of Science ®Google Scholar
• Pirker R, Ramlau RA, Schuette W, et al. Safety and efficacy of darbepoetin alpha in previously untreated extensive-stage small-cell lung cancer treated with platinum plus etoposide. J Clin Oncol 2008;26:2342-9
   PubMed Web of Science ®Google Scholar
• Glaspy JA, Jadeja JS, Justice G, et al. A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease. Cancer 2003;97:1312-20
   PubMed Web of Science ®Google Scholar
• Hesketh PJ, Arena F, Patel D, et al. A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignancies. Cancer 2004;100:859-68
   PubMed Web of Science ®Google Scholar
• Kotasek D, Canon JL, Mateos MV, et al. A randomized, controlled trial comparing darbepoetin alfa correction/maintenance dosing with weekly dosing for treating chemotherapy-induced anemia. Curr Med Res Opin 2007;23:1387-401
   PubMed Web of Science ®Google Scholar
• Justice G, Kessler JF, Jadeja J, et al. A randomized, multicenter study of subcutaneous and intravenous darbepoetin alfa for the treatment of chemotherapy-induced anemia. Ann Oncol 2005;16:1192-8
   PubMed Web of Science ®Google Scholar
• Glaspy J, Kotasek D, Canon JL, et al. Meta-analysis of the effects on safety of front-loading (FL), every-2-week (Q2W), and Q3W dosing of darbepoetin alfa (DA) in patients (pts) with chemotherapy-induced anemia (CIA). J Clin Oncol 2012;30(Suppl): abstr e19511
   Google Scholar
• Auerbach M, Ballard H, Trout JR, et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol 2004;22:1301-7
   PubMed Web of Science ®Google Scholar
• Bastit L, Vandebroek A, Altintas S, et al. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J Clin Oncol 2008;26:1611-18
   PubMed Web of Science ®Google Scholar
• Hedenus M, Birgegard G, Nasman P, et al. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study. Leukemia 2007;21:627-32
   PubMed Web of Science ®Google Scholar
• Henry DH, Dahl NV, Auerbach M, et al. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist 2007;12:231-42
   PubMed Web of Science ®Google Scholar
• Pedrazzoli P, Farris A, Del PS, et al. Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. J Clin Oncol 2008;26:1619-25
   PubMed Web of Science ®Google Scholar
• Steensma DP, Sloan JA, Dakhil SR, et al. Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia. J Clin Oncol 2011;29:97-105
   PubMed Web of Science ®Google Scholar
• Aapro M, Beguin Y, Birgegard G, et al. Too-low iron doses and too many dropouts in negative iron trial? (correspondence). J Clin Oncol 2011;29:e525-6
   PubMed Web of Science ®Google Scholar
• Steensma D, Sloan JA, Loprinzi CL. Reply to Aapro et al. J Clin Oncol 2011;29:e527
   Google Scholar
• Rizzo JD, Brouwers M, Hurley P, et al. American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol 2010;28:4996-5010
   PubMed Web of Science ®Google Scholar
• Schrijvers D, De SH, Roila F. Erythropoiesis-stimulating agents in the treatment of anaemia in cancer patients: ESMO Clinical Practice Guidelines for use. Ann Oncol 2010;21(Suppl 5):v244-7
   PubMed Web of Science ®Google Scholar
• Esquerdo G, Llorca C, Cervera JM, et al. Effectiveness of darbepoetin alfa in a cohort of oncology patients with chemotherapy-induced anaemia. Relationship between variation in three fatigue-specific quality of life questionnaire scores and change in haemoglobin level. Clin Transl Oncol 2011;13:341-7
   PubMed Web of Science ®Google Scholar
• Vadhan-Raj S, Mirtsching B, Charu V, et al. Assessment of hematologic effects and fatigue in cancer patients with chemotherapy-induced anemia given darbepoetin alfa every two weeks. J Support Oncol 2003;1:131-8
   PubMedGoogle Scholar
• Varricchio CG, Sloan JA. The need for and characteristics of randomized, phase III trials to evaluate symptom management in patients with cancer (letter to editor). J Natl Cancer Inst 2002;94:1184-5
   PubMed Web of Science ®Google Scholar
• Glaspy J, Henry D, Patel R, et al. Effects of chemotherapy on endogenous erythropoietin levels and the pharmacokinetics and erythropoietic response of darbepoetin alfa: a randomised clinical trial of synchronous versus asynchronous dosing of darbepoetin alfa. Eur J Cancer 2005;41:1140-9
   PubMed Web of Science ®Google Scholar
• Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003;362:1255-60
   PubMed Web of Science ®Google Scholar
• Overgaard J, Hoff C, Hansen S, et al. Randomized study of darbepoetin alfa as modifier of radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC): Final outcome of the DAHANCA 10 trial (abstract). J Clin Oncol 2009;27:6007
   Google Scholar
• Wright JR, Ung YC, Julian JA, et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 2007;25:1027-32
   PubMed Web of Science ®Google Scholar
• Smith RE Jr, Aapro MS, Ludwig H, et al. Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. J Clin Oncol 2008;26:1040-50
   PubMed Web of Science ®Google Scholar
• Untch M, Fasching PA, Konecny GE, et al. PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel +/− darbepoetin alfa in primary breast cancer – results at the time of surgery. Ann Oncol 2011;22:1988-98
   PubMed Web of Science ®Google Scholar
• Leyland-Jones B, Semiglazov V, Pawlicki M, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 2005;23:5960-72
   PubMed Web of Science ®Google Scholar
• Nitz U, Gluz O, Oberhoff C, et al. Adjuvant chemotherapy with or without darbepoetin alpha in node-positive breast cancer: survival and quality of life analysis from the prospective randomized WSG ARA Plus trial. Cancer Res 2011;71(Suppl):PD07-06
   Google Scholar
• Untch M, von MG, Konecny GE, et al. PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer – outcome on prognosis. Ann Oncol 2011;22:1999-2006
   PubMed Web of Science ®Google Scholar
• Delarue R, Haioun C, Coiffier B, et al. Survival effect of darbepoetin alfa in patients with diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: the LNH03-6B study. J Clin Oncol 2011;29(Suppl): abstr 9048
   Google Scholar
• Ludwig H, Crawford J, Osterborg A, et al. Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia. J Clin Oncol 2009;27:2838-47
   PubMed Web of Science ®Google Scholar
• Bennett CL, Silver SM, Djulbegovic B, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008;299:914-24
   PubMed Web of Science ®Google Scholar
• Hedenus M, Vansteenkiste J, Kotasek D, et al. Darbepoetin alfa for the treatment of chemotherapy-induced anemia: disease progression and survival analysis from four randomized, double-blind, placebo-controlled trials. J Clin Oncol 2005;23:6941-8
   PubMed Web of Science ®Google Scholar
• Aapro MS, Link H. September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents. Oncologist 2008;13(Suppl 3):33-6
   PubMed Web of Science ®Google Scholar
• Bokemeyer C, Aapro MS, Courdi A, et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 2007;43:258-70
   PubMed Web of Science ®Google Scholar
• Thomas G, Ali S, Hoebers FJ, et al. Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer. Gynecol Oncol 2008;108:317-25
   PubMed Web of Science ®Google Scholar
• Arcasoy MO. Erythropoiesis-stimulating agent use in cancer: preclinical and clinical perspectives. Clin Cancer Res 2008;14:4685-90
   PubMed Web of Science ®Google Scholar
• Jelkmann W, Bohlius J, Hallek M, et al. The erythropoietin receptor in normal and cancer tissues. Crit Rev Oncol Hematol 2008;67:39-61
   PubMed Web of Science ®Google Scholar
• Sinclair AM, Todd MD, Forsythe K, et al. Expression and function of erythropoietin receptors in tumors: implications for the use of erythropoiesis-stimulating agents in cancer patients. Cancer 2007;110:477-88
   PubMed Web of Science ®Google Scholar
• Elliott S, Sinclair AM. The Effect of erythropoietin on normal and neoplastic cells. Biologics 2012;6:163-89
   PubMedGoogle Scholar
• Elliott S, Busse L, Swift S, et al. Lack of expression and function of erythropoietin receptors in the kidney. Nephrol Dial Transplant 2012;27:2733-45
   PubMed Web of Science ®Google Scholar
• Swift S, Ellison AR, Kassner P, et al. Absence of functional EpoR expression in human tumor cell lines. Blood 2010;115:4254-63
   PubMed Web of Science ®Google Scholar
• Tonelli M, Hemmelgarn B, Reiman T, et al. Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis. CMAJ 2009;180:E62-71
   PubMed Web of Science ®Google Scholar
• Bohlius J, Schmidlin K, Brillant C, et al. Erythropoietin or darbepoetin for patients with cancer – meta-analysis based on individual patient data. Cochrane Database Syst Rev 2009;3:CD007303
   PubMed Web of Science ®Google Scholar
• Glaspy J, Crawford J, Vansteenkiste J, et al. Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br J Cancer 2010;102:301-15
   PubMed Web of Science ®Google Scholar
• Vansteenkiste J, Glaspy J, Henry D, et al. Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: study-level and patient-level meta-analyses. Lung Cancer 2012;76:478-85
   PubMed Web of Science ®Google Scholar
• Amgen, Johnson & Johnson. FDA Briefing Document (for the Oncologic Drugs Advisory Committee). Food and Drug Administration, 13/3/2008
   Google Scholar
• Hedenus M, Osterborg A, Tomita D, et al. Effects of erythropoiesis-stimulating agents on survival and other outcomes in patients with lymphoproliferative malignancies: a study-level meta-analysis. Leuk Lymphoma 2012;53(11):2151-8
   Google Scholar
• US Food and Drug Administration. Public Health Advisory: erythropoiesis-stimulating agents (ESAs). FDA, 9/3/2007
   Google Scholar
• Amgen. Aranesp Summary of Product Characteristics. 10.Sep.2012
   Google Scholar
• Aerts J, Swieboda-Sadlej A, Karanikiotis C, et al. Use of darbepoetin alfa in European clinical practice for the management of chemotherapy-induced anaemia in four tumour types – final data from the CHOICE study. Curr Med Res Opin 2012;28:1089-99
   PubMed Web of Science ®Google Scholar
• Bittner N, Kipkova A, Móciková H, et al. Current management of chemotherapy-induced anemia with darbepoetin alfa – the Apriori study. J Clin Oncol 2011;29(Suppl):e19723
   Google Scholar
• Bustos A, Alvarez R, Aramburo PM, et al. Evaluation of clinical use and effectiveness of darbepoetin alfa in cancer patients with chemotherapy-induced anemia. Curr Med Res Opin 2012;28:57-67
   PubMed Web of Science ®Google Scholar
• Van Belle S, Swieboda-Sadlej A, Karanikiotis C, et al. A final analysis from the CHOICE study examining darbepoetin alfa use for chemotherapy-induced anaemia in current European clinical practice with data presented by baseline haemoglobin level. Curr Med Res Opin 2012;28:1079-87
   PubMed Web of Science ®Google Scholar
• Pirker R, Collins H, Legg JC, et al. Rate of hemoglobin (Hb) decline from <10 g/dL to <9 g/dL in placebo-treated patients (pts) receiving chemotherapy: a pooled analysis of data from 6 randomized darbepoetin alfa trials. J Clin Oncol 2011;29(Suppl):e19637
   Google Scholar
• Pirolli M, Collins H, Hulnick S, et al. Rate of hemoglobin (Hb) decline from <10 g/dL to <9 g/dL by electronic medical-record (EMR) evaluation in community oncology patients (pts) receiving chemotherapy in the absence of erythropoiesis-stimulating agents (ESAs). J Clin Oncol 2011;29(Suppl):abstr e19625
   Google Scholar
• Vansteenkiste J, Hedenus M, Gascon P, et al. Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level <10 g/dL versus > or =10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trial. BMC Cancer 2009;9:311
   PubMed Web of Science ®Google Scholar
• Pongsanon K, Benjapibal M, Ruengkhachorn I. Prognostic significance of hemoglobin levels in patients with primary epithelial ovarian carcinoma undergoing platinum-based chemotherapy. Asian Pac J Cancer Prev 2011;12:131-6
   PubMed Web of Science ®Google Scholar
• Van Belle SJ, Cocquyt V. Impact of haemoglobin levels on the outcome of cancers treated with chemotherapy. Crit Rev Oncol Hematol 2003;47:1-11
   PubMed Web of Science ®Google Scholar
• Balducci L. Anemia, cancer, and aging. Cancer Control 2003;10:478-86
   PubMedGoogle Scholar
• Ludwig H, Wedding U, Van Belle S. Anaemia in elderly patients with cancer: focus on chemotherapy-induced anaemia. J Geriatr Oncol 2012;3:256-64
   Web of Science ®Google Scholar